AC Immune CEO Dr. Andrea Pfeifer to Retire; Board Chair Dr. Martin Zügel Appointed Interim CEO
ACIU sits 89% above its 52-week low of $1.51.
Summary
AC Immune announced that co-founder and CEO Dr. Andrea Pfeifer will retire at the upcoming AGM, with Board Chair Dr. Martin Zügel stepping in as interim CEO.
Key Events · Executive and Board Changes · ACIU
-
CEO Retirement Announced
Dr. Andrea Pfeifer, co-founder and CEO for 23 years, will retire from her role at the upcoming Annual General Meeting on June 11, 2026, to spend more time with her family. Her decision was not due to any disagreement with the company.
-
Interim CEO Appointed
Dr. Martin Zügel, the current Chair of the Board, has been appointed interim CEO while the search for a permanent successor is conducted. Dr. Zügel has 30 years of experience in multinational healthcare companies.
-
Outgoing CEO to Remain as Advisor
Dr. Pfeifer will be engaged as an Advisor to facilitate the transition and will be appointed as Honorary Chair of the Board of Directors and Co-Chair of the Scientific Advisory Board.
Analysis · ACIU · Life Sciences
The retirement of a co-founder and long-serving CEO is a significant leadership transition for any company, especially in the biotech sector where continuity of vision is critical. While the departure is stated as voluntary for personal reasons and not due to disagreement, and the outgoing CEO will remain an advisor, the market will closely watch the search for a permanent successor and the company's strategic direction under interim leadership. This follows a period of positive clinical and financial updates for the company.
At the time of this filing, ACIU was trading at $2.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $288M. The 52-week trading range was $1.51 to $4.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.